Last reviewed · How we verify
SD Fluzone Vaccine
SD Fluzone Vaccine is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
SD Fluzone Vaccine is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | SD Fluzone Vaccine |
|---|---|
| Also known as | Fluzone influenza vaccine |
| Sponsor | Insight Therapeutics, LLC |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from three or four seasonal flu strains, which trigger both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies and T-cell responses that provide protection against infection by matching circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness, redness, or swelling
- Fever
- Myalgia (muscle aches)
- Fatigue
- Headache
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |